|
rs1805192
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese.
|
16965392 |
2006 |
|
rs1805192
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After adjustment for age, sex, smoking habit, family history and family income, an increased risk of CRC was observed for the C/T + T/T genotype compared to the C/C genotype of the C161T polymorphism (odds ratio = 1.61, 95% confidence interval: 1.10-2.36), whereas no significant association was found for Pro12Ala (odds ratio = 1.06, 95% confidence interval: 0.70-1.61).
|
16108832 |
2005 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Compared with those individuals with the CC allele, increasing risk of CRC with increasing red meat intake was more pronounced among individuals with T alleles of PPARγC161T (rs3856806), but the association was not significant.
|
30489355 |
2019 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
On the contrary, two other SNPs, PLA2G2A c.435+230C>T and PPARG c.1431C>T (p.His477His), were associated with a decrease in CRC risk.
|
18992148 |
2008 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The stratified analysis revealed that the <i>PPARG</i> r</span>s3856806 C>T polymorphism also increased the risk of CRC, especially in male, ≥61 years old, never smoking, never drinking, BMI ≥ 24 kg/m<sup>2</sup>, colon cancer and rectum cancer subgroups.
|
30838172 |
2019 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Several studies evaluated the association between peroxisome proliferators-activated receptor gamma (PPARγ) Pro12Ala (rs1801282), and His477His (rs3856806) polymorphisms and the risk of colorectal cancer (CRC).However, the results were not stable.
|
29970681 |
2018 |
|
rs9858822
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association between rs9858822 in the PPARG gene and colorectal cancer was statistically significant at the end of the second stage (OR per allele = 1.36, Bonferroni-adjusted P = 0.045), based on the "effective" number of markers in stage II (n = 306).
|
24045924 |
2013 |